Skip to content

The effect of curcumin-piperine dietary supplement in people with type 2 diabetes and hypertriglyceridemia

The effect of curcumin-piperine dietary supplement on lipid profile, glycemic, inflammatory and blood pressure indicators in people with type 2 diabetes and hypertriglyceridemia: randomized double-blind clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20121216011763N50
Enrollment
80
Registered
2021-02-16
Start date
2020-12-10
Completion date
Unknown
Last updated
2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus. Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group: will receive one capsule daily (containing 495 mg of curcumin extract + 5 mg of piperine) along with diet and exercise recommendations. The supplement is from Sami

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Willingness to participate in the study Age: 18-65 years old Type 2 diabetes (fasting blood sugar above 126 mg / dL) Hypertriglyceridemia (triglyceride above 150 mg / dL) has been diagnosed.

Exclusion criteria

Exclusion criteria: Pregnancy and lactation People with type 1 diabetes and tasteless diabetes Insulin injection Smoking Heart, lung, kidney, malignant cancer, immune system disorders, addiction or mental illness

Design outcomes

Primary

MeasureTime frame
Serum lipids. Timepoint: Blood samples are taken at the beginning and end of the study. Method of measurement: Blood samples.;Blood glucose. Timepoint: Blood samples are taken at the beginning and end of the study. Method of measurement: Blood samples.

Secondary

MeasureTime frame
Cholesterol. Timepoint: Before and after the intervention. Method of measurement: Blood samples using enzymatic methods.;High-density lipoprotein (HDL). Timepoint: Before and after the intervention. Method of measurement: Blood samples using enzymatic methods.;Low density lipoprotein (LDL). Timepoint: Before and after the intervention. Method of measurement: Blood samples using enzymatic methods.;Inflammatory factor (hs-CRP). Timepoint: Before and after the intervention. Method of measurement: Blood samples using enzymatic methods.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Gholamreza Askari

Esfahan University of Medical Sciences

askari@mui.ac.ir+98 31 3792 3171

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026